» Articles » PMID: 24893836

Three Midlife Strategies to Prevent Cognitive Impairment Due to Alzheimer's Disease

Overview
Journal Climacteric
Publisher Informa Healthcare
Date 2014 Jun 5
PMID 24893836
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The slow, progressive accumulation of pathology characteristic of Alzheimer's disease is the principal determinant of cognitive decline leading to dementia. Risk-reduction strategies during midlife focus on raising the clinical threshold for the appearance of cognitive symptoms and on reducing the extent of Alzheimer pathology. Best available evidence suggests an approach based on three, conceptually distinct strategies. (1) Raise the threshold for cognitive symptoms by improving brain health. To achieve this goal, the tactic is to reduce cerebrovascular risks mediated by hypertension, diabetes, cigarette smoking, and hyperlipidemia. (2) Raise the threshold for cognitive symptoms by enhancing cognitive reserve. Here, tactics focus on mental stimulation associated with occupation, leisure activities and social engagement. (3) Reduce the burden of Alzheimer pathology. The most promising tactic toward this end is regular aerobic exercise. Tactics in support of strategies to reduce cognitive impairment due to Alzheimer pathology are not yet substantiated by robust, consistent clinical trial evidence. There is pressing need for well-designed pragmatic trials to provide stronger evidence on preventive strategies for late-life cognitive decline and dementia.

Citing Articles

Do Not Worry That Generative AI May Compromise Human Creativity or Intelligence in the Future: It Already Has.

Sternberg R J Intell. 2024; 12(7).

PMID: 39057189 PMC: 11278271. DOI: 10.3390/jintelligence12070069.


Interplay between microglia and environmental risk factors in Alzheimer's disease.

Zhang M, Liang C, Chen X, Cai Y, Cui L Neural Regen Res. 2023; 19(8):1718-1727.

PMID: 38103237 PMC: 10960290. DOI: 10.4103/1673-5374.389745.


Malignant Brain Aging: The Formidable Link Between Dysregulated Signaling Through Mechanistic Target of Rapamycin Pathways and Alzheimer's Disease (Type 3 Diabetes).

de la Monte S J Alzheimers Dis. 2023; 95(4):1301-1337.

PMID: 37718817 PMC: 10896181. DOI: 10.3233/JAD-230555.


Skeletal muscle adiposity is a novel risk factor for poor cognition in African Caribbean women.

Acevedo-Fontanez A, Cvejkus R, Zmuda J, Kuipers A, Barinas-Mitchell E, Sekikawa A Obesity (Silver Spring). 2023; 31(9):2398-2406.

PMID: 37475604 PMC: 10680092. DOI: 10.1002/oby.23816.


Multi-angles of smoking and mild cognitive impairment: is the association mediated by sleep duration?.

Hu M, Yin H, Shu X, Jia Y, Leng M, Chen L Neurol Sci. 2019; 40(5):1019-1027.

PMID: 30778881 DOI: 10.1007/s10072-019-03750-5.


References
1.
Potter G, Helms M, Plassman B . Associations of job demands and intelligence with cognitive performance among men in late life. Neurology. 2007; 70(19 Pt 2):1803-8. PMC: 3873817. DOI: 10.1212/01.wnl.0000295506.58497.7e. View

2.
Szekely C, Green R, Breitner J, Ostbye T, Beiser A, Corrada M . No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology. 2008; 70(24):2291-8. PMC: 2755238. DOI: 10.1212/01.wnl.0000313933.17796.f6. View

3.
Bove R, Secor E, Chibnik L, Barnes L, Schneider J, Bennett D . Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2013; 82(3):222-9. PMC: 3902759. DOI: 10.1212/WNL.0000000000000033. View

4.
. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement. 2013; 9(6):714-23. PMC: 3823756. DOI: 10.1016/j.jalz.2012.11.012. View

5.
Um H, Kang E, Leem Y, Cho I, Yang C, Chae K . Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. Int J Mol Med. 2008; 22(4):529-39. View